LENZ Therapeutics, Inc. (NASDAQ:LENZ - Get Free Report) has been given an average recommendation of "Buy" by the seven analysts that are presently covering the company, MarketBeat Ratings reports. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $35.40.
A number of equities research analysts recently weighed in on the stock. William Blair raised shares of LENZ Therapeutics to a "strong-buy" rating in a research note on Friday, August 30th. Piper Sandler reissued an "overweight" rating and set a $36.00 price target on shares of LENZ Therapeutics in a research note on Thursday, August 15th. Raymond James initiated coverage on shares of LENZ Therapeutics in a research note on Friday, September 27th. They issued an "outperform" rating and a $37.00 target price for the company. Finally, HC Wainwright initiated coverage on shares of LENZ Therapeutics in a research note on Monday, August 12th. They issued a "buy" rating and a $38.00 target price for the company.
Get Our Latest Report on LENZ
LENZ Therapeutics Price Performance
NASDAQ:LENZ traded up $2.00 on Friday, reaching $27.02. The stock had a trading volume of 117,095 shares, compared to its average volume of 171,613. LENZ Therapeutics has a 1-year low of $14.07 and a 1-year high of $31.00. The stock has a fifty day moving average price of $23.49 and a 200-day moving average price of $20.48.
LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.40) earnings per share for the quarter, topping analysts' consensus estimates of ($0.49) by $0.09. On average, equities analysts anticipate that LENZ Therapeutics will post -3.15 EPS for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the stock. Jacobs Levy Equity Management Inc. acquired a new position in LENZ Therapeutics during the first quarter worth $830,000. Jennison Associates LLC acquired a new stake in LENZ Therapeutics in the first quarter valued at $3,009,000. Vanguard Group Inc. acquired a new stake in LENZ Therapeutics in the first quarter valued at $4,621,000. Bank of New York Mellon Corp lifted its stake in LENZ Therapeutics by 255.4% in the second quarter. Bank of New York Mellon Corp now owns 39,737 shares of the company's stock valued at $687,000 after acquiring an additional 28,556 shares during the last quarter. Finally, Marshall Wace LLP acquired a new stake in LENZ Therapeutics in the second quarter valued at $390,000. Institutional investors and hedge funds own 54.32% of the company's stock.
LENZ Therapeutics Company Profile
(
Get Free ReportLENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Recommended Stories
Before you consider LENZ Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LENZ Therapeutics wasn't on the list.
While LENZ Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
